Clinical efficacy of long-term treatment in patients with vascular dementia
https://doi.org/10.20538/1682-0363-2011-2-92-97
Abstract
To study efficacy and safety of prolonged course of cerebrolysin therapy in vascular dementia, 48 patients, aged from 59—77 years, with mild and moderate dementia have been studied. A potential of 3-years course of cerebrolysin therapy to slow down the progression of cognitive impairment in patients with vascular dementia has been studied in the open study. Efficacy and safety of cerebrolysin were assessed clinically and with a battery of widespread scales and neuropsychological tests. The improvement of cognitive, functional and motor activities in patients with mild and moderate dementia indicate the high effectiveness of cerebrolysin. A prolonged therapy allows to prevent the progression of cognitive impairment and development of vascular dementia.
About the Author
I. A. Suvorova
Иркутский государственный институт усовершенствования врачей
Russian Federation
Russian Federation
References
1. Гаврилова С.И. Диагностика и лечение болезни Альцгеймера: практическое руководство. М., 2002. 43 с.
2. Гаврилова С.И. и др. Применение церебролизина в комплексной патогенетической терапии болезни Альцгеймера. Международный симпозиум «Церебролизин: фармакологические эффекты и место в клинической практике». М., 2002. С. 90-95.
3. Левин О.С. Принципы долговременной терапии деменции//Рус. мед. журн. 2006. № 24. С. 1772-1779.
4. Левин О.С. Подходы к оптимизации терапии деменции//Журн. неврологии и психиатрии. 2008. № 11. С. 106-111.
5. Chui H.C. et al. Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers//Neurology. 1992. V. 42. P. 473.
6. Farlow M.R. et al. Treatment options of Alzheimer's disease//Dementia and Geriatric Cognitive Disorders. 2008. № 25. P. 408-422.
7. Fazekas F. et al. Pathologic correlates of incidental MRI white matter signal hyperintensities//Neurology. 1993. V. 43. P. 1683-1689.
8. Folstein M. et al. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician//J. of Psychiatric Research. 1975. № 12. Р. 189-198.
9. Galasko D. et al. An Inventory to Assess Activities of Daily Living for Clinical Trials in Alzheimer´s Disease//Alzheimer Disease and Associated Disorders. 1997. № 11. Р. 533-539.
10. Gauthier S. Clinical diagnosis and management of Alzheimer's disease//Informahealthcare. London, 2007. P. 363.
11. McKeel D.W. et al. Dementia. Oxford: Clinical Publishing, 2006. P. 196.
12. Moessler H. A randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of Cerebrolysin in patients with vascular dementia. Clinical Study Report. Moscow, 2008. 115 p.
13. Panisset M. Клинический экспертный доклад о терапевтической эффективности церебролизина при лечении деменции. М., 2002. 25 с.
14. Reiner M. et al. Therapeutic results with Cerebrolysin in the treatment of dementia//Wien Mod Wochenschr. 1997. № 147. P. 426-431.
15. Roman G. et al. Vascular Dementia : diagnostic criteria for research studies. Report from the NINDS-AIREN international workshop // Neurology. 1993. № 43. Р. 250-260.
16. Rosen W.G. et al. A new rating scale for Alzheimer's Disease//Am. J. of Geriatric Psychiatry. 1984. № 141. Р. 1356-1364.
17. The ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Research. Geneva, 1993. P. 36-40.
Review
For citations:
Suvorova I.A. Clinical efficacy of long-term treatment in patients with vascular dementia. Bulletin of Siberian Medicine. 2011;10(2):92-97. (In Russ.) https://doi.org/10.20538/1682-0363-2011-2-92-97
Views:
538
Email this article 